Xiaoyi Zhang
China Pharmaceutical University(CN)Tianjin Medical University General Hospital(CN)Changshu No.1 People's Hospital(CN)Henan Polytechnic University(CN)
Publications by Year
Research Areas
Chemokine receptors and signaling, Immunotherapy and Immune Responses, Monoclonal and Polyclonal Antibodies Research, Drug Transport and Resistance Mechanisms, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Identification of LY2510924, a Novel Cyclic Peptide CXCR4 Antagonist That Exhibits Antitumor Activities in Solid Tumor and Breast Cancer Metastatic Models(2014)142 cited
- → Impact of obesity upon prostate cancer-associated mortality: A meta-analysis of 17 cohort studies(2014)92 cited
- → Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies(2016)58 cited
- → Circular RNA La‐related RNA‐binding protein 4 correlates with reduced tumor stage, as well as better prognosis, and promotes chemosensitivity to doxorubicin in breast cancer(2020)34 cited
- → A Jak2-selective inhibitor potently reverses the immune suppression by modulating the tumor microenvironment for cancer immunotherapy(2017)32 cited
- → Prognostic Value of Radiomic Features of 18F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells